|
|
|
|
Genzyme signs manufacturing deal with Hospira
CAMBRIDGE, Mass.-Biotechnology company Genzyme Corp.is contracting manufacturing for its key products to Hospira Inc. for an undisclosed amount, the company announced last month. The deal involves the manufacturing of the genetic disorder drugs ...
|
|
|
PREVIEW-Genzyme competition may get clearer at conference
By Toni Clarke BOSTON, Feb 8 (Reuters) - Genzyme Corp, Shire Plc and Protalix Biotherapeutics Inc will each be presenting data this week that could give hints as to how the competitive landscape for Gaucher disease treatments could look a year or two from now....
|
|
|
PREVIEW-Genzyme competition may get clearer at conference
BOSTON, Feb 8 (Reuters) - Genzyme Corp, Shire Plc and Protalix Biotherapeutics Inc will each be presenting data this week that could give hints as to how the competitive landscape for Gaucher disease treatments could look a year or two from now.Cambridge,...
|
|
|
Genzyme competition may get clearer at conference
* Genzyme, Shire, Protalix to present Gaucher data BOSTON, Feb 8 (Reuters) - Genzyme Corp, Shire Plc and Protalix Biotherapeutics Inc will each be presenting data this week that could give hints as to how the competitive landscape for Gaucher disease treatments...
|
|
|
PREVIEW-Genzyme competition may get clearer at conference
* What: Lysosomal Disease Network World Congress * When: Feb.10-12 * Genzyme, Shire, Protalix to present Gaucher data BOSTON, Feb 8 (Reuters) - Genzyme Corp <GENZ.O>, Shire Plc <SHP.L> and Protalix Biotherapeutics Inc <PLX.A> will each be...
|
|
|
STOCKS NEWS US-Goldman adds St. Jude to 'Conviction Sell' list
stock market report 0820 EST 8Feb2010-Goldman adds St.Jude to 'Conviction Sell' list ------------------------------------------------------------------------------ Goldman Sachs added St. Jude Medical Inc to its conviction sell list, and cut price targets...
|
|
|
FDA wants more info on Protalix Gaucher drug
Protalix Biotherapeutics has suffered a setback in its bid to compete with Genzymes Cerezyme after regulators in the USA asked for more information on the Israeli companys experimental Gaucher disease drug taliglucerase alfa.Protalix filed a New Drug...
|
|
|
Genzyme hires manufacturing chief
NEW YORK - Cambridge-based Genzyme Corp., the drug maker forced to close a plant last year because of contamination, has hired the former head of manufacturing at Eli Lilly & Co., Scott Canute.He joins the company as president of manufacturing and...
|
|
|
UBS analyst upgrades Genzyme as company resumes shipping enzyme drugs Cerezyme and Fabrazyme
NEW YORK A UBS analyst upgraded shares of Genzyme Wednesday, saying the biotechnology company should recover now that it has resumed shipments of two of its drugs.Maged Shenouda upgraded Genzyme stock to "Buy" from "Neutral," and raised his price target to ...
|
|
|
Pfizer's Hedge Pays Off
Recs 0 //Create your sharelet with desired properties and set button element to false object //Tie customized button to This button functionality.element Disney Buys Marvel! David Gardner called it! Hes up 1,334%! See what Davids recommending that you...
|
|
|
Pfizer's Hedge Pays Off
You almost want to say that Pfizer (NYSE: PFE) saw this coming.When the drug giant licensed Protalix BioTherapeutics' (NYSE: PLX) Gaucher disease treatment, taliglucerase alfa, two months ago, I characterized the license as a steal. Turns out Pfizer's low...
|
|
|
Ahead of the Bell: Genzyme upgraded to 'Buy'
NEW YORK (AP) - A UBS analyst upgraded shares of Genzyme Wednesday, saying the biotechnology company should recover now that it has resumed shipments of two of its drugs.Maged Shenouda upgraded Genzyme stock to 'Buy' from 'Neutral,' and raised his price...
|
|
|
Genzyme Names Global Manufacturing President
CAMBRIDGE, Mass.--Biotechnology company Genzyme Corp.said Wednesday it named Scott Canute president of global manufacturing and corporate operations. Canute previously lead manufacturing at Eli Lilly & Co. At Genzyme, he will oversee production of a...
|
|
|
Genzyme names global manufacturing president
CAMBRIDGE, Mass.--Biotechnology company Genzyme Corp. said Wednesday it named Scott Canute president of global manufacturing and corporate operations. Canute previously lead manufacturing at Eli Lilly & Co. At Genzyme, he will oversee production of...
|
|
|
Ahead of the Bell: Genzyme upgraded to 'Buy'
NEW YORK (AP) -- A UBS analyst upgraded shares of Genzyme Wednesday, saying the biotechnology company should recover now that it has resumed shipments of two of its drugs.Maged Shenouda upgraded Genzyme stock to "Buy" from "Neutral," and raised his price target...
|
|
|
Protalix shares dip as FDA poses new Gaucher drug query
Shares of Israel's Protalix Biotherapeutics slid 14 percent after the FDA bounced back its marketing application for a new Gaucher disease drug with a request for more information.The agency had some follow-up questions that focus on the manufacturing...
|
|
|
From the Editor: Ordinary Measures
Everything I needed to know I learned in Freshman Chemistry 101 To cast your vote, log in or become a member.This quick, one-time registration gives you access to members-only site benefits. 1 vote Text size: - + For Years, pharma has been the villain in...
|
|
|
UPDATE 2-Protalix says FDA seeks more data on Gaucher drug
* Protalix expects to submit more data during Q2 * Says request primarily related to manufacturing process * Shares down 14 pct in pre-market trade (Adds details, share movement) Feb 2 (Reuters) - Israeli biotechnology company Protalix Biotherapeutics Inc <...
|
|
|
UPDATE 2-Protalix says FDA seeks more data on Gaucher drug
PROTALIX EXPECTS TO SUBMIT MORE DATA DURING Q2 * Says request primarily related to manufacturing process * Shares down 14 pct in pre-market trade (Adds details, share movement) Feb 2 (Reuters) - Israeli biotechnology company Protalix Biotherapeutics Inc said U...
|
|
|
Genzyme's Outlook Stabilizing
Genzyme Corp.(GENZ) reports fourth-quarter results on February 17, with the current Zacks Consensus Estimate at 20 cents per share. Recent revisions to the quarterly estimate have been in both directions, with a very modest upward (positive) bias. Of the...
|
|
|
Genzyme's Outlook Stabilizing - Zibb.com
Company: Genzyme Corp.(GENZ) Genzyme Corp. (GENZ) reports fourth-quarter results on February 17, with the current Zacks Consensus Estimate at 20 cents per share. Recent revisions to the quarterly estimate have been in both directions, with a very modest...
|
|
|
Genzyme's Outlook Stabilizing
Genzyme Corp.(GENZ) reports fourth-quarter results on February 17, with the current Zacks Consensus Estimate at 20 cents per share. Recent revisions to the quarterly estimate have been in both directions, with a very modest upward (positive) bias. Of the...
|
|
|
Genzyme to add 500 jobs
Genzyme Corp., which is working to end rationing of two key drugs and return to full-scale production by midyear at its troubled Allston Landing plant, expects to hire more than 500 workers in Massachusetts this year, mostly at its headquarters in Cambridge and...
|
|
|
Genzyme chief expects to increase Mass. workforce
Genzyme Corp., which is working to end rationing of two key drugs and return to full-scale production by midyear at its troubled Allston Landing plant, expects to hire more than 500 workers in Massachusetts this year, mostly at its headquarters in Cambridge and...
|
|
|
Genzyme chief expects to increase Mass. workforce by at least 500
Genzyme Corp., which is working to end rationing of two key drugs and return to full-scale production by midyear at its troubled Allston Landing plant, expects to hire more than 500 workers in Massachusetts this year, mostly at its headquarters in Cambridge and...
|
